NT-3 Recombinant Protein
- Known as:
- NT-3 Recombinant Protein
- Catalog number:
- ZR-40-565
- Product Quantity:
- 0.01 mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- NT-3 Recombinant Protein
Related genes to: NT-3 Recombinant Protein
- Gene:
- GCNT4 NIH gene
- Name:
- glucosaminyl (N-acetyl) transferase 4
- Previous symbol:
- LINC01336
- Synonyms:
- C2GNT3
- Chromosome:
- 5q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-06
- Date modifiied:
- 2018-10-18
- Gene:
- INTS3 NIH gene
- Name:
- integrator complex subunit 3
- Previous symbol:
- C1orf60
- Synonyms:
- FLJ21919, INT3, SOSS-A
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-13
- Date modifiied:
- 2014-11-19
- Gene:
- NOTCH4 NIH gene
- Name:
- notch receptor 4
- Previous symbol:
- INT3
- Synonyms:
- -
- Chromosome:
- 6p21.32
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-04
- Date modifiied:
- 2019-01-03
- Gene:
- NT3 NIH gene
- Name:
- 3'-nucleotidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- reserved
- Locus Type:
- unknown
- Date approved:
- 1989-02-23
- Date modifiied:
- 2013-03-27
- Gene:
- SLC25A6 NIH gene
- Name:
- solute carrier family 25 member 6
- Previous symbol:
- ANT3
- Synonyms:
- ANT3Y, MGC17525
- Chromosome:
- Xp22.32 and Yp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 1990-08-03
- Date modifiied:
- 2016-02-18
Related products to: NT-3 Recombinant Protein
Related articles to: NT-3 Recombinant Protein
- Resistance to 5-fluorouracil (5-FU) necessitates its administration in combination with other drugs to enhance the clinical outcome. Oxymatrine (OMT) exhibits antitumor and anti-inflammatory activities. This study aimed to investigate the synergistic antitumor effect of OMT with 5-FU in A549 cells. - Source: PubMed
Publication date: 2026/07/25
Zeng GuofangLuo FeiZeng QiaoliWang ZhiqiangGuo Runmin - Aberrant glycosylation contributes to tumour progression and metastatic dissemination. Beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) is involved in poly-N-acetyllactosamine synthesis, but its role in colon adenocarcinoma remains insufficiently characterised. This retrospective single-centre study evaluated B3GNT3 expression and its association with clinicopathological parameters using TCGA and CPTAC data, immunohistochemistry in 97 colon adenocarcinomas, Western blot analysis, and transmission electron microscopy. TCGA analysis showed no significant differences in B3GNT3 mRNA expression between normal and tumour tissues. In contrast, CPTAC, immunohistochemistry, and Western blot analyses demonstrated increased B3GNT3 protein expression in tumour tissue compared with non-neoplastic mucosa. Immunohistochemical expression was assessed semi-quantitatively using the immunoreactive score (IRS). Lower B3GNT3 expression was associated with advanced stage and node-positive status. Because pathological stage and lymph node status are interrelated clinicopathological variables in colon adenocarcinoma, these findings were interpreted as partially overlapping associations rather than independent biological endpoints. Exploratory ROC and logistic regression analyses supported these cohort-level associations; however, the ROC-derived IRS cut-off was not externally validated, and regression models were interpreted cautiously. TEM/immunogold analysis supported Golgi/secretory-pathway localisation but was descriptive. Overall, B3GNT3 expression was associated with clinicopathological features in this retrospective cohort. - Source: PubMed
Publication date: 2026/07/14
Piecuch AdamPiecuch Jerzy ZBajdak-Rusinek KarolinaMichalski MarekMatysiak NataliaBrzozowa-Zasada Marlena - Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death worldwide. Despite advances in surgery, targeted therapy, and immunotherapy, the 5-year survival rate of advanced LUAD remains below 20%, indicating an urgent need for reliable molecular biomarkers for early detection and prognosis. In this study, the authors hypothesized that three consistently upregulated genes could act as effective diagnostic and prognostic biomarkers for LUAD. The authors analyzed transcriptomic data from two independent cohorts, TCGA-LUAD (535 tumors, 59 normal samples) and GSE115002 (52 tumors, 52 matched normal samples), to screen differentially expressed genes. Three core genes-B3GNT3, FERMT1, and SPP1-were consistently overexpressed in LUAD tumors in both datasets. These genes showed excellent diagnostic performance, with AUC values above 0.95 in TCGA-LUAD and high accuracy in GSE115002. Survival analysis showed that high expression of each gene was significantly associated with shorter overall and disease-free survival, and multivariate Cox regression verified their independent prognostic value. Functional enrichment analysis indicated that these three genes participate in epithelial-mesenchymal transition, extracellular matrix remodeling, and immune suppression, all of which are closely related to LUAD invasion and metastasis. The authors further constructed a prognostic nomogram combining the three genes and TNM stage, achieving a concordance index of 0.743 and demonstrating good predictive performance. These findings confirm that B3GNT3, FERMT1, and SPP1 are promising diagnostic and prognostic biomarkers for LUAD, supporting the clinical application in risk stratification and management. - Source: PubMed
Publication date: 2026/06/30
Lin YuhuiChen ZeJia BinWang ZhengZhang LihuaLi MingjieLiu BichenChen LihuiChen Xiaoting - Abnormal glycolysis is one of the hallmarks of cancer and plays a significant role in its progression. This study investigates the association between glycolysis genes and the progression of lung adenocarcinoma (LUAD). Utilizing various bioinformatics techniques, the research explores the heterogeneity of glycolysis genes in different LUAD cell types, identifies glycolysis-related prognostic signatures (GRPS). We obtained one training set for model construction from the Cancer Genome Atlas (TCGA) database, and also obtained four LUAD gene expression datasets as validation sets from the Gene Expression Omnibus (GEO) database. The single-cell RNA sequencing (scRNA seq) data also comes from the GEO database. Firstly, the "limma" R package was used to identify differentially expressed glycolysis related genes, and a machine learning computational framework composed of multiple combinations was used to preliminarily screen for glycolysis related prognostic markers (GRPS) in LUAD. Based on these GRPS, prognostic features were developed and validated through survival analysis, column chart development, and ROC curve analysis. The ssGSEA algorithm, ESTIMATE algorithm, and seven integrated computational algorithms from the TIMER 2.0 database were used to analyze the immune cell infiltration patterns of different risk groups. Analyze scRNA seq data to evaluate the distribution of GRPS and intercellular communication among various cell types, and further determine the core GRPS through the "hdWGCNA" and "ConstructNetwork" packages. In addition, we also evaluated the responsiveness of high and low-risk groups to 198 drugs using the "OncoPredict" software package. Result: We found that the glycolytic activity score of tumor tissue was significantly higher than that of normal tissue, and a total of 49 upregulated genes and 15 downregulated genes were selected from the total. Based on a machine learning computational framework, a total of 8 GRPS were screened, which constitute the prognostic features of LUAD patients. This feature demonstrates strong prognostic value, as confirmed by univariate and multivariate Cox regression analysis. Significant differences in tumor microenvironment (TME) immune infiltration were observed between high and low-risk groups. ScRNA seq revealed the distribution and expression of cell type specific GRPS, particularly in T cells, epithelial cells, and fibroblasts, while also revealing the strong cell-cell communication ability of the high GRPS group. The hdWGCNA analysis ultimately identified five core GRPS, namely DDIT4, FKBP4, CHPF, EFNA3, and B3GNT3. In addition, there are significant differences in sensitivity to most drugs between high-risk and low-risk cohorts, with WIKI4 and Lapatinib negatively correlated with risk scores, while Doramapimod and Niraparib positively correlated with risk scores. This study established a GRPS based risk feature for LUAD, demonstrating strong predictive power for prognosis assessment. The drug sensitivity results also provide drug guidance for the clinical application of this feature, all of which provide important clinical utility for the prognosis of LUAD. At the same time, the intercellular communication network was plotted based on the GRPS score, providing insights into the pathogenesis of LUAD and offering new ideas for developing targeted therapies and precision medicine methods. - Source: PubMed
Publication date: 2026/04/13
Tang YalanXiao JundanZhong XiaoweiChen Zhigang - The aim of this study was to explore the prognostic significance of necrotic cell death triggered by sodium overload (NECSO)-related genes in lung adenocarcinoma (LUAD) and construct a prognostic model with high predictive efficiency. The findings will enable a precise stratification of the prognostic risk of patients with LUAD. Analysis of the constructed prognostic model, immune cell infiltration, and tumor mutational burden (TMB) will facilitate the development of individualized precision medical protocols. - Source: PubMed
Publication date: 2026/03/02
Liang LiWang XiaoqiLiu HuihuiHuang TingZhu QuanLu FangguoChen Chunjing